These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 16297185)

  • 1. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus.
    Albrecht J; Taylor L; Berlin JA; Dulay S; Ang G; Fakharzadeh S; Kantor J; Kim E; Militello G; McGinnis K; Richardson S; Treat J; Vittorio C; Van Voorhees A; Werth VP
    J Invest Dermatol; 2005 Nov; 125(5):889-94. PubMed ID: 16297185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric dermatologists and rheumatologists.
    Kushner CJ; Tarazi M; Gaffney RG; Feng R; Ardalan K; Brandling-Bennett HA; Castelo-Soccio L; Chang JC; Chiu YE; Gmuca S; Hunt RD; Kahn PJ; Knight AM; Mehta J; Pearson DR; Treat JR; Wan J; Yeguez AC; Concha JSS; Patel B; Okawa J; Arkin LM; Werth VP
    Br J Dermatol; 2019 Jan; 180(1):165-171. PubMed ID: 30033560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology.
    Krathen MS; Dunham J; Gaines E; Junkins-Hopkins J; Kim E; Kolasinski SL; Kovarik C; Kwan-Morley J; Okawa J; Propert K; Rogers N; Rose M; Thomas P; Troxel AB; Van Voorhees A; Feldt JV; Weber AL; Werth VP
    Arthritis Rheum; 2008 Mar; 59(3):338-44. PubMed ID: 18311759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures.
    Jolly M; Kazmi N; Mikolaitis RA; Sequeira W; Block JA
    J Am Acad Dermatol; 2013 Apr; 68(4):618-623. PubMed ID: 23107310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The study of Cutaneous Lupus Erythematosus Disease Area and Severity Index in Indian patients with systemic lupus erythematosus.
    Salphale P; Danda D; Chandrashekar L; Peter D; Jayaseeli N; George R
    Lupus; 2011 Dec; 20(14):1510-7. PubMed ID: 21997966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of cutaneous disease activity in early lupus and its correlation with quality of life: a cross-sectional study.
    Hinduja N; Mv P; Padhee S; Maikap D; Padhan P; Kar HK; Misra R; Srinivas CR; Ahmed S
    Rheumatol Int; 2023 Oct; 43(10):1835-1840. PubMed ID: 37310437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI).
    Yokogawa N; Kato Y; Sugii S; Inada S
    Mod Rheumatol; 2012 Apr; 22(2):249-55. PubMed ID: 21842436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument.
    Klein RS; Morganroth PA; Werth VP
    Rheum Dis Clin North Am; 2010 Feb; 36(1):33-51, vii. PubMed ID: 20202590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous lupus erythematosus: factors related to cutaneous activity and damage in a cohort of 260 patients from A Coruña, Spain.
    Arévalo-Bermúdez MDP; Paradela S; Balboa-Barreiro V; Fonseca E
    Lupus; 2020 Aug; 29(9):1021-1030. PubMed ID: 32539659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus.
    Kuhn A; Meuth AM; Bein D; Amler S; Beissert S; Böhm M; Brehler R; Ehrchen J; Grundmann S; Haust M; Ruland V; Schiller M; Schulz P; Ständer S; Sauerland C; Köpcke W; Luger TA; Bonsmann G
    Br J Dermatol; 2010 Jul; 163(1):83-92. PubMed ID: 20394621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cutaneous lupus erythematosus disease area and severity index: a responsive instrument to measure activity and damage in patients with cutaneous lupus erythematosus.
    Bonilla-Martinez ZL; Albrecht J; Troxel AB; Taylor L; Okawa J; Dulay S; Werth VP
    Arch Dermatol; 2008 Feb; 144(2):173-80. PubMed ID: 18283174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validity and sensitivity to change of laser Doppler imaging as a novel objective outcome measure for cutaneous lupus erythematosus.
    Md Yusof MY; Britton J; Edward S; Hensor EMA; Goodfield MJ; Laws PM; Emery P; Wittmann M; Vital EM
    Lupus; 2019 Oct; 28(11):1320-1328. PubMed ID: 31522626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of disease activity and damage in different subtypes of cutaneous lupus erythematosus using the CLASI.
    Bein D; Kuehn E; Meuth AM; Amler S; Haust M; Nyberg F; Sauerland C; Luger TA; Bonsmann G; Kuhn A
    J Eur Acad Dermatol Venereol; 2011 Jun; 25(6):652-9. PubMed ID: 20849444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus.
    Albrecht J; Werth VP
    Dermatol Ther; 2007; 20(2):93-101. PubMed ID: 17537137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring disease activity and damage in discoid lupus erythematosus.
    Wahie S; McColl E; Reynolds NJ; Meggitt SJ
    Br J Dermatol; 2010 May; 162(5):1030-7. PubMed ID: 20199547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI).
    Yokogawa N; Tanikawa A; Amagai M; Kato Y; Momose Y; Arai S; Eto H; Ikeda T; Furukawa F
    Mod Rheumatol; 2013 Mar; 23(2):318-22. PubMed ID: 22581095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of disease activity and damage in patients with cutaneous lupus erythematosus.
    Ker KJ; Teske NM; Feng R; Chong BF; Werth VP
    J Am Acad Dermatol; 2018 Dec; 79(6):1053-1060.e3. PubMed ID: 29969701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity.
    American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria
    Arthritis Rheum; 2004 Nov; 50(11):3418-26. PubMed ID: 15529383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus.
    Sigges J; Biazar C; Landmann A; Ruland V; Patsinakidis N; Amler S; Bonsmann G; Kuhn A;
    Autoimmun Rev; 2013 May; 12(7):694-702. PubMed ID: 23220353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus.
    Klein R; Moghadam-Kia S; LoMonico J; Okawa J; Coley C; Taylor L; Troxel AB; Werth VP
    Arch Dermatol; 2011 Feb; 147(2):203-8. PubMed ID: 21339447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.